QQQ   323.77 (+2.11%)
AAPL   168.25 (+2.02%)
MSFT   288.86 (+2.32%)
META   178.54 (+5.94%)
GOOGL   119.52 (+2.48%)
AMZN   142.27 (+3.22%)
TSLA   867.97 (+2.11%)
NVDA   174.94 (+2.39%)
NIO   19.37 (+1.04%)
BABA   90.73 (-0.50%)
AMD   96.91 (+1.43%)
MU   59.85 (+1.18%)
T   18.15 (+0.28%)
CGC   2.86 (-0.35%)
GE   76.02 (+1.45%)
F   15.36 (+1.12%)
DIS   110.97 (+2.63%)
AMC   21.91 (-2.41%)
PYPL   97.40 (+3.09%)
PFE   49.90 (+0.24%)
NFLX   238.97 (+3.93%)
QQQ   323.77 (+2.11%)
AAPL   168.25 (+2.02%)
MSFT   288.86 (+2.32%)
META   178.54 (+5.94%)
GOOGL   119.52 (+2.48%)
AMZN   142.27 (+3.22%)
TSLA   867.97 (+2.11%)
NVDA   174.94 (+2.39%)
NIO   19.37 (+1.04%)
BABA   90.73 (-0.50%)
AMD   96.91 (+1.43%)
MU   59.85 (+1.18%)
T   18.15 (+0.28%)
CGC   2.86 (-0.35%)
GE   76.02 (+1.45%)
F   15.36 (+1.12%)
DIS   110.97 (+2.63%)
AMC   21.91 (-2.41%)
PYPL   97.40 (+3.09%)
PFE   49.90 (+0.24%)
NFLX   238.97 (+3.93%)
QQQ   323.77 (+2.11%)
AAPL   168.25 (+2.02%)
MSFT   288.86 (+2.32%)
META   178.54 (+5.94%)
GOOGL   119.52 (+2.48%)
AMZN   142.27 (+3.22%)
TSLA   867.97 (+2.11%)
NVDA   174.94 (+2.39%)
NIO   19.37 (+1.04%)
BABA   90.73 (-0.50%)
AMD   96.91 (+1.43%)
MU   59.85 (+1.18%)
T   18.15 (+0.28%)
CGC   2.86 (-0.35%)
GE   76.02 (+1.45%)
F   15.36 (+1.12%)
DIS   110.97 (+2.63%)
AMC   21.91 (-2.41%)
PYPL   97.40 (+3.09%)
PFE   49.90 (+0.24%)
NFLX   238.97 (+3.93%)
QQQ   323.77 (+2.11%)
AAPL   168.25 (+2.02%)
MSFT   288.86 (+2.32%)
META   178.54 (+5.94%)
GOOGL   119.52 (+2.48%)
AMZN   142.27 (+3.22%)
TSLA   867.97 (+2.11%)
NVDA   174.94 (+2.39%)
NIO   19.37 (+1.04%)
BABA   90.73 (-0.50%)
AMD   96.91 (+1.43%)
MU   59.85 (+1.18%)
T   18.15 (+0.28%)
CGC   2.86 (-0.35%)
GE   76.02 (+1.45%)
F   15.36 (+1.12%)
DIS   110.97 (+2.63%)
AMC   21.91 (-2.41%)
PYPL   97.40 (+3.09%)
PFE   49.90 (+0.24%)
NFLX   238.97 (+3.93%)
NASDAQ:AGRX

Agile Therapeutics - AGRX Stock Forecast, Price & News

$0.62
-0.06 (-8.14%)
(As of 08/10/2022 09:53 AM ET)
Add
Compare
Today's Range
$0.62
▼
$0.65
50-Day Range
$0.50
▼
$2.41
52-Week Range
$0.49
▼
$50.40
Volume
27,887 shs
Average Volume
4.58 million shs
Market Capitalization
$2.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.00

Agile Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19,068.4% Upside
$130.00 Price Target
Short Interest
Healthy
2.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.82mentions of Agile Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($0.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

See Top Rated MarketRank™ Stocks Here
AGRX stock logo

About Agile Therapeutics (NASDAQ:AGRX) Stock

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Wall Street Analysts Forecast Growth

AGRX has been the subject of several recent research reports. Maxim Group raised shares of Agile Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, July 26th. StockNews.com initiated coverage on shares of Agile Therapeutics in a research note on Wednesday, August 3rd. They set a "sell" rating for the company.

Agile Therapeutics Stock Up 11.2 %

Shares of AGRX Stock traded up $0.07 during trading hours on Tuesday, reaching $0.68. 21,556,759 shares of the stock traded hands, compared to its average volume of 4,578,660. Agile Therapeutics has a 1-year low of $0.49 and a 1-year high of $50.40. The business has a fifty day moving average price of $0.90 and a 200 day moving average price of $6.40. The firm has a market capitalization of $3.08 million, a PE ratio of -0.03 and a beta of 1.23.

Agile Therapeutics (NASDAQ:AGRX - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share (EPS) for the quarter. Agile Therapeutics had a negative net margin of 1,209.95% and a negative return on equity of 599.24%. The firm had revenue of $1.76 million for the quarter. Research analysts expect that Agile Therapeutics will post -2.19 earnings per share for the current fiscal year.

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Stock News Headlines

August 9, 2022 | americanbankingnews.com
Agile Therapeutics (AGRX) Scheduled to Post Quarterly Earnings on Thursday
July 28, 2022 | finance.yahoo.com
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
August 10, 2022 | Investing Trends (Ad)
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
July 28, 2022 | americanbankingnews.com
Agile Therapeutics (NASDAQ:AGRX) Stock Rating Upgraded by Maxim Group
July 26, 2022 | finance.yahoo.com
Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock
July 12, 2022 | finance.yahoo.com
Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla'
July 12, 2022 | finance.yahoo.com
HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling
July 12, 2022 | finance.yahoo.com
Agile Therapeutics Updates Second Quarter 2022 Guidance
August 10, 2022 | Investing Trends (Ad)
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
July 11, 2022 | seekingalpha.com
Agile gains as H.C. Wainwright sees 630% upside potential
July 10, 2022 | benzinga.com
Agile Therapeutics to Participate in Maxim Group...
July 8, 2022 | finance.yahoo.com
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
July 6, 2022 | finance.yahoo.com
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
July 1, 2022 | markets.businessinsider.com
Dow Surges 200 Points; Agile Therapeutics Shares Slide
July 1, 2022 | seekingalpha.com
Agile Therapeutics prices $24M upsized stock offering
July 1, 2022 | finance.yahoo.com
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
July 1, 2022 | finance.yahoo.com
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
July 1, 2022 | seekingalpha.com
Allena, Trevi top healthcare gainers; while Agile, Icosavax lead losers' pack
June 29, 2022 | barrons.com
Thinking about buying stock in Kezar Life Sciences, Evofem Biosciences, Agile Therapeutics, Sutro Biopharma, or Wejo Group?
June 28, 2022 | finance.yahoo.com
Healthcare Breakthroughs: KZR, NMLSF, AGRX, LMLLF Report Latest Advances in Novel Therapeutics for Inflammatory Diseases, Oncology, and Autism
May 27, 2022 | nasdaq.com
Don’t Settle! The Success of Self-Advocacy in Advancing Women’s Wellness
May 17, 2022 | seekingalpha.com
XERS, AGRX and LHDX among mid-day movers
May 17, 2022 | finance.yahoo.com
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
May 13, 2022 | seekingalpha.com
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q1 2022 Results - Earnings Call Transcript
May 5, 2022 | finance.yahoo.com
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
May 3, 2022 | finance.yahoo.com
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
April 28, 2022 | finanznachrichten.de
Agile Therapeutics, Inc.: Agile Therapeutics Announces 1-For-40 Reverse Stock Split
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Company Calendar

Last Earnings
5/12/2022
Today
8/10/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGRX
CUSIP
N/A
CIK
1261249
Web
www.agiletherapeutics.com
Phone
(609) 683-1880
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$130.00
High Stock Price Forecast
$160.00
Low Stock Price Forecast
$100.00
Forecasted Upside/Downside
+20,766.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($26.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,890,000.00
Net Margins
-1,209.95%
Pretax Margin
-1,291.28%
Return on Equity
-599.24%
Return on Assets
-176.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.56
Quick Ratio
0.45

Sales & Book Value

Annual Sales
$4.10 million
Price / Sales
0.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
4,542,000
Free Float
4,329,000
Market Cap
$2.83 million
Optionable
Optionable
Beta
1.23

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AGRX Stock - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

What is Agile Therapeutics' stock price forecast for 2022?

2 analysts have issued 1 year price objectives for Agile Therapeutics' shares. Their AGRX share price forecasts range from $100.00 to $160.00. On average, they predict the company's stock price to reach $130.00 in the next year. This suggests a possible upside of 19,068.4% from the stock's current price.
View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts.

How has Agile Therapeutics' stock performed in 2022?

Agile Therapeutics' stock was trading at $19.5240 at the start of the year. Since then, AGRX stock has decreased by 96.5% and is now trading at $0.6782.
View the best growth stocks for 2022 here.

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our AGRX earnings forecast.

How can I listen to Agile Therapeutics' earnings call?

Agile Therapeutics will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Thursday, May, 12th. The specialty pharmaceutical company reported ($3.78) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.76 million for the quarter. Agile Therapeutics had a negative net margin of 1,209.95% and a negative trailing twelve-month return on equity of 599.24%.

When did Agile Therapeutics' stock split?

Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $0.68.

How much money does Agile Therapeutics make?

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.08 million and generates $4.10 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($26.98) on an earnings per share basis.

How many employees does Agile Therapeutics have?

Agile Therapeutics employs 28 workers across the globe.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.

This page (NASDAQ:AGRX) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.